April 23, 2021 -- A group of more than 35 clinical researchers, academic institutions, healthcare provider organizations, patient advocacy groups, and private companies has formed to establish standards and guidance in multicancer early detection (MCED), an emerging field.
MCED tests use blood draws, urine, saliva, or stool samples to rapidly screen for multiple types of cancer at once, potentially catching and treating disease earlier. The consortium will evaluate the clinical and public health value of the tests for earlier cancer detection and treatment and establish standards for their use in routine medical care.
Founding members of the consortium include Blue Cross and Blue Shield, the Cancer Support Community, the Dana-Farber Cancer Institute, Friends of Cancer Research, Grail, the Knight Cancer Institute, Oregon Health & Science University, the Milken Institute, the Sarah Cannon Research Institute, Stand Up To Cancer, and Thrive.
Copyright © 2021 LabPulse.com